Gene therapy approaches delivering neurotrophic factors have offered promising results in both pre-clinical and clinical trials of Parkinson's disease (PD). However, failure of glial cell line-derived neurotrophic factor in phase II clinical trials has sparked a search for other trophic factors which may retain efficacy in the clinic. Direct protein injections of one such factor, insulin-like growth factor 1 (IGF-1), in a rodent model of PD has demonstrated impressive protection of dopaminergic neurons against 6-hydroxydopamine (6-OHDA) toxicity. However, protein infusion is associated with surgical risks, pump failure and significant costs. We therefore used lentiviral vectors to deliver Igf-1, with a particular focus on the novel integration-deficient lentiviral vectors (IDLVs). A neuron-specific promoter, from the human synapsin 1 gene, excellent for gene expression from IDLVs, was additionally used to enhance Igf-1 expression. An investigation of neurotrophic effects on primary rat neuronal cultures demonstrated that neurons transduced with IDLV-Igf-1 vectors had complete protection upon withdrawal of exogenous trophic support. Striatal transduction of such vectors into 6-OHDA-lesioned rats, however, provided neither protection of dopaminergic substantia nigra neurons nor improvement of animal behavior.
Introduction
Parkinson's disease (PD) results from a gradual loss of neurons within the dopaminergic substantia nigra pars compacta (SNpc) and their projections to the striatum 1 . Therapeutic strategies using trophic factors have offered encouraging results in both pre-clinical and open-label clinical trials of PD [2] [3] [4] [5] [6] . However, administration of the most promising factor, glial cell line-derived neurotrophic factor (GDNF), was unsuccessful in double blind, phase II clinical trials 7 . Hence, the search for other neurotrophic factors has been stepped up [4] [5] [6] 8 . One such factor is insulin-like growth factor 1 (IGF-1).
IGF-1 is well known as a peripheral growth factor (secreted mainly by hepatocytes) that regulates cell metabolism and tissue remodeling 9 . In recent years, a role of IGF-1 within the central nervous system (CNS) has been identified, appearing to be both neuroprotective and neurotrophic, and important in the maintenance of adult CNS homeostasis 10, 11 . IGF-1 is also considered a pro-survival factor, upregulated in all types of brain injuries 12 . IGF-1 exerts its multiple effects through binding to IGF-1 receptors, phosphorylation of which activates multiple downstream signaling pathways, resulting in inhibition of apoptosis and regulation of both cell differentiation and cell proliferation [13] [14] [15] .
The exact role of IGF-1 in PD remains unclear, with studies reporting a decrease in plasma levels associated with cognitive decline 16 . Conversely, in post-mortem PD samples, an increase in plasma IGF-1 levels was observed 17 , suggesting that there may be a compensatory increase in IGF-1 levels due to the ongoing cell loss. Guan et al. 18 and Offen et al. 19 demonstrated IGF-1 neuroprotection against 6-hydroxydopamine (6-OHDA) toxicity in human neuroblastoma and rodent neuronal cell cultures. Other studies using intracerebral injections of IGF-1 protein, after 6-OHDA lesioning of the nigrostriatal pathway, have suggested that IGF-1 administration can prevent dopaminergic cell loss and behavioral deficits in this pre-clinical animal model of PD 18, 20, 21 . However, direct protein infusion via a surgically implanted pump has a number of disadvantages, including limited distribution, device-related side effects and activation of the immune response 7, 22 . An alternative approach, which may overcome these disadvantages, is the use of gene therapy to deliver the gene for IGF-1 through a viral vector system. Numerous reports have shown both efficient and stable expression of GDNF from lentiviral vectors (LVs) in pre-clinical animal models of PD [23] [24] [25] [26] [27] . We have previously demonstrated that the novel integration-deficient LVs (IDLVs) are as efficient as their standard integration-proficient counterparts (IPLVs) at transducing rodent eye and brain cells in vivo 28 but have enhanced biosafety due to their reduced risk of insertional mutagenesis 28, 29 . Our recent data have confirmed efficient and longlasting in vivo transduction with IDLV-hGDNF, mediating therapeutic effects in a PD rat model 30 .
In the present study, the potential neuroprotective effects of IGF-1 were investigated through IDLVmediated expression, with IPLV-Igf-1 vectors used as controls. To maximize the levels of transgene expression, which can be addressed by the choice of promoters specific to target cells 31-33 , we initially examined transduction efficiency and cell-type specificity of LVs through expression of the gene encoding enhanced green fluorescent protein (eGFP). We compared vectors driven by the cytomegalovirus promoter (CMVp), human glial fibrillary acidic protein promoter (GFAPp) and human synapsin 1 promoter (SYNp). In particular, LV-mediated in vivo eGFP expression from IDLVSYNp vectors displayed efficient, long-term, and comparable transduction efficacy with their integrating counterparts. Following vector transduction in rat primary ventral mesencephalic cell cultures and 6-OHDA-lesioned rats, the neuronal specificity of LV-SYNp vectors, beneficial to enhance Igf-1 expression 34 , was ascertained. Further investigation of LV-mediated IGF-1 neuroprotection demonstrated enhanced in vitro survival of rat cortical neurons against withdrawal of exogenous trophic factors. Igf-1 expression from LVs was subsequently confirmed in 6-OHDA rat model of PD although neither dopaminergic cell survival nor animal behavioral recovery was improved following vector transduction.
Materials and Methods
Lentiviral vector production and titration: Concentrated stocks of the 3rd generation lentiviral vectors, both IPLVs and IDLVs, were produced by calcium phosphate transfection in HEK-293T cells as previously described 28 . Lentiviral transfer plasmids used in this study were pRRLsc-CMVp-eGFP-W, pRRLsc-hGFAPp-eGFP-W, pRRLsc-hSYNp-eGFP-W, pRRLsc-CMVp-Gdnf-IRES-eGFP-W, pRRLsc-SFFVpeGFP-CMVp-Igf-1-W, and pRRLsc-SFFVp-eGFP-hSYNp-Igf-1-W; Gdnf and Igf-1 cDNAs were from rat.
All vectors were self-inactivating, contained a central polypurine tract/central termination sequence (cPPT/cTS) and Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE, abbreviated as W on plasmid names), and were pseudotyped with the vesicular stomatitis virus G protein (VSV-G) envelope. Viral titres were quantified by either flow cytometry using a FACSCanto II (BD Biosciences, UK), qPCR using Rotogen (QIAgen, UK) as described 28 , or by p24 ELISA kit (SAIC, Frederick, Maryland, USA) following the manufacturer's instructions.
Animals:
Animal procedures were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986. Sprague-Dawley rats (Charles River, UK) were maintained in a standard 12-hour light/dark cycle with free access to food and water. For primary cell cultures, E14-E15 embryos were used for ventral mesencephalic (VM) cultures whilst E17-E18 embryos were harvested for cortical neuronal cultures. For in vivo work, 35 male rats weighing 250-300 g at the beginning of the study were housed 2-3 rats/cage and were split randomly into experimental groups, either for 5-month eGFP experiment or 6-week IGF-1 experiment.
Preparation of primary cultures of embryonic brain cells: Rat embryos were rapidly removed and kept in ice-cold dissection buffer containing 1X Hank's balanced salt solution (Invitrogen, UK), 100 units/ml penicillin (PAA, UK), 100 μg/ml streptomycin (PAA, UK), and 100 μM ascorbic acid (Sigma Aldrich, UK). The ventral mesencephalons containing the subtantia nigra or cortices were dissected under a Wild M3Z dissecting microscope (Wild Heerbrugg, Switzerland) with illumination support by a KL2500 LCD instrument (Schott UK Ltd., UK). Brain tissues were dissociated in 0.05% trypsin/EDTA (PAA, UK) supplemented with 0.02% DNaseI (Promega, UK) for 5-20 min at 37 o C. Tissues were washed twice in culture medium prior to de-aggregation by repeated pipetting (p1000, p200, p20, and p10 pipettors). VM or cortical neuronal culture medium included neurobasal medium (Invitrogen, UK), 2% B27 (Invitrogen, UK), 0.25% GlutaMax (Invitrogen, UK), 1% FBS (PAA, UK), and 100 μM ascorbic acid (Sigma Aldrich, UK); 10 ng/ml TGF-βIII was additionally added into VM neuronal cultures. VM astroglial culture medium included DMEM (PAA, UK), 1% N2 (Invitrogen, UK) and 10% FBS. The cell suspension was then passed through a 40-100 μm cell strainer and subsequently centrifuged at 80-200 g for 5 min. The cell pellet was resuspended in pre-warmed culture medium. Live cells were counted by 0.2% tryphan blue staining (Sigma Aldrich, UK). For VM neuronal cultures, 100 µl cell suspension containing 10 5 live cells was plated onto a 13 mm coverslip (Thermo Scientific, UK), which was pre-coated overnight with 50 μg/ml poly-D-lysine and placed inside a well of a 24-well plate.
After 30 minutes for cell adhesion, each well was carefully topped up with 500 μl culture medium. For 
LV transduction in vitro:
Cell culture medium was changed 2 hours prior to vector transduction.
Concentrated vector stocks were diluted in medium for an optimized MOI 10 (eGFP transducing units/ml) or MOI 30 (qPCR vector units/ml) and added gently to the wells; mock cells received no vector.
Trophic support withdrawal strategy: Cortical neuronal cultures had the medium changed at day 1 in vitro, 2 hours prior to transduction with IDLVs at MOI 30 (qPCR vector units/ml), including: CMVpeGFP, CMVp-Gdnf-IRES-eGFP, SFFVp-eGFP-CMVp-Igf-1, and SFFVp-eGFP-SYNp-Igf-1 vectors. Cells were maintained for 3 days before withdrawal of exogenous trophic factors. For this, the medium was aspirated; normal culture medium was added into trophic factor-supported groups whereas only neurobasal medium was added to trophic factor-free groups. Cell viability was assessed by MTT assay after an additional 3 days.
MTT assay: Cell viability was evaluated by using a colorimetric assay employing MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma Aldrich, UK). A final concentration of 0.5 mg/ml MTT was added to cell cultures and subsequently incubated at 37ºC for 3 hours. Formazan crystals produced in this reaction were solubilized in dimethyl sulfoxide (VWR, UK). The optical cell density in each well was then measured by spectrometric analysis at OD570, using Gen5 data analysis software (BioTek, UK). (1:3000, Sigma, UK) for neurons; rabbit anti-GFAP (1:500, DAKO, UK) for astrocytes; rabbit anti-Iba1
(1:500, WAKO, UK) for microglia; rabbit anti-TH (1:1000, Millipore, UK) for dopaminergic neurons; rabbit anti-VGLUT1 (1:500, Synaptic systems, Germany) for glutamatergic neurons; or rabbit anti-GAD67 (1:50, Synaptic systems, Germany) for GABAergic neurons. After 3 washes in 1X PBS, cells were incubated with the corresponding secondary antibodies diluted in 1% BSA blocking buffer at room temperature, for an hour, in the dark. The antibody (1:500, Invitrogen, UK) was either goat antirabbit AlexaFluor555 or goat anti-mouse AlexaFluor555. After another 3 washes in 1X PBS, cells were incubated with 1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) for 15 min, in the dark. Three washes in 1X PBS were then performed. Images of cells were subsequently captured and counted. Cells incubated with only primary or secondary antibody were used as negative controls for the staining. 
Drug-induced rotational asymmetry tests:
In the IGF-1 experiment, animal behavior was tested weekly, from one week after 6-OHDA lesioning for a period of 4 weeks. Amphetamine-induced rotational tests were carried out first, followed by apomorphine tests 3 days later. In each test, animals were acclimatized in 40 cm-diameter bowls for 30 min prior to injection with amphetamine (5 mg/kg, i.p; Sigma Aldrich, UK) or apomorphine (1 mg/kg, i.p; Tocris, UK). Net rotational asymmetry was assessed for 90 min post-injection as one whole head to tail revolution, with contralateral and ipsilateral turns being scored separately.
IGF-1/GDNF detection by ELISA:
In the in vitro experiment, cortical neuronal cultures were collected at days 3 and 6 post-transduction with IDLV-Igf-1 or -Gdnf vectors. In the in vivo experiment, rats receiving IPLV-or IDLV-Igf-1 vectors, or mock-treated animals were sacrificed with CO2 followed by cervical dislocation. The striata were dissected and snap-frozen in liquid nitrogen. Tissue was homogenized in complete lysis buffer (Roche, UK) and centrifuged at 14000 g, 4 o C for 15 min. Levels of IGF-1 or GDNF that were produced in either cell cultures or rat striata were determined with a rat IGF-1 ELISA kit (R&D System, UK) or a human GDNF ELISA kit (Promega, UK) following the manufacturers' instructions.
Immunohistochemistry: Rats were sacrificed as described above. Whole brains were fixed in 4% PFA for 3 days at 4 o C. Coronal striata containing sections from the eGFP experiment or nigra containing sections from the IGF-1 experiment were sliced on a vibrating microtome (Campden Instruments, UK) at 50 µm thickness and kept in ice-cold 1X PBS. Sections were subsequently incubated in 1% BSA blocking buffer (Sigma Aldrich, UK) for an hour. Striata containing sections were incubated with primary antibody, either mouse anti-NeuN (1:500, Millipore, UK), rabbit anti-GFAP (1:500, DAKO, UK) or rabbit anti-Iba1 (1:500, WAKO, UK) whilst SN containing sections were incubated with rabbit anti-TH (1:1000, Millipore, UK) overnight at 4 o C, followed by three washes in 1X PBS. Sections were then incubated with goat anti-mouse or goat anti-rabbit AlexaFluor555 antibody (1:500, Invitrogen, UK) as appropriate for 1 hour, in the dark. After three washes in 1X PBS, sections were incubated with 1 µg/ml DAPI (Sigma Aldrich, UK) for 15 min and mounted onto SuperFrost slides.
Image capture: Both cultured cells and brain sections were visualized under an inverted fluorescence Axio Observer D1 microscope. Images were taken with an AxioCam combined with AxioVision software. Equipment and software were purchased from Carl Zeiss, UK.
Cell counting: Since cultured cells dispersed unevenly, 9 fields/well were selected manually at the same positions in all wells to avoid bias and for more accurate statistical analysis. An image was captured from each field and the cell numbers were counted manually using ImageJ software (National Institutes of Health, Maryland, US). DAPI + cell nuclei were scored to obtain the total cell number. The DAPI channel was subsequently merged with another fluorescence channel to score the total number of a specific cell type. Averages of cell numbers from the 9 fields were then used to obtain the total and marker-positive cell numbers within each well. (Figure 1f) .
In astroglial cultures containing 36% astrocytes and 1% neurons (as characterized in Figure S2b) , the cell-type specificity of LV-SYNp vectors was significantly different of that observed with the other vectors in both the total number of cells expressing eGFP and eGFP intensity. Significantly higher transduction efficiency of IPLVs compared to IDLVs was observed only in eGFP intensity from CMVpeGFP vectors (Figures 2a, b) . Representative images are shown in Figure 2c . We subsequently quantified specific cell types expressing eGFP in the transduced astroglial cultures, with a focus on astrocytes and neurons. Although there was no statistically significant difference in the number of total astrocytes (p = 0.14) or neurons (p = 0.15) between cultures (Figure S3) , the percentage of eGFP-expressing cells from the various promoters used was significantly different (Figures 2d, e) . 
In vivo neuronal specificity of LV-SYNp vectors
In a bid to determine whether the neuronal specificity of LV-SYNp vectors was maintained in vivo, in particular in the PD animal model, IPLV-or IDLV-SYNp-eGFP vectors were injected into the right striatum of rats, followed by 6-OHDA lesioning two weeks later. Brains were harvested 5 months post vector injection. Successful transduction with widespread eGFP expression within the striatum was demonstrated (Figures 3a, b) . No eGFP expression was detected in the non-injected striatal hemispheres ( Figure 3c) ; however, there was anterograde presence of eGFP in the SNpr, from the striatal injection site (Figure 3d) . Quantification of levels of eGFP intensity showed no significant differences in transduction efficacy between IPLV-and IDLV-SYNp vectors (p = 0.12, Figure 3e ).
Further cell identification by morphology and marker expression confirmed that the majority of neurons were transduced; no significant astrocyte or microglia transduction was noticed (Figures 3f,   g ). These results are consistent with the in vitro findings, confirming the neuronal specificity of LVSYNp vectors. The data in particular demonstrated comparable transduction efficiency of IDLVs with their counterparts in the post-mitotic CNS environment. Using commercially available ELISA kits, we measured the level of IGF-1 (Figure 4c ) and GDNF ( Figure   4d ) produced in the transduced neuronal cultures. Transgenic production of IGF-1 was efficient and independent of trophic support and vector promoter (4.3 -5.5 ng/ml at day 3, and 5.8 -6.0 ng/ml at day 6). GDNF production was similarly efficient at 3 days post-transduction (~5.6 ng/ml), but seemed slightly reduced at day 6 (~4.7 ng/ml) and even lower in the absence of trophic support (~3.7 ng/ml), matching the culture viability as shown by MTT assay (Figure 4a 
IGF-1 protective effects on rat primary cortical neuronal cultures

Lack of IGF-1 protective effects on dopaminergic neurons of 6-OHDA-lesioned rats
We subsequently investigated LV-Igf-1 transduction in a 6-OHDA rat model of PD. IPLVs or IDLVs expressing Igf-1 were injected into the right striatum of rats, which then received a partial unilateral lesion with 6-OHDA two weeks after vector transduction. The amount of IGF-1 produced in the striatum was determined by ELISA 6 weeks post-vector administration (Figure 5a) showing no significant differences in the levels of IGF-1 in the contralateral hemispheres between groups (p = 0.92). As expected, the levels in LV-Igf-1-injected hemispheres were significantly higher than in contralateral hemispheres and mock animals, regardless of vector integration proficiency or promoter type (p < 0.001). Differences in efficacy between vectors were noticed, with IPLVs being more efficient than IDLVs, and SYNp promoter being particularly efficient in the IPLV configuration.
IPLVs boosted IGF-1 levels 5 to 7-fold, while IDLVs provided about 2.5-fold increases (Figures 5a, b) . The potential of IGF-1 exerting beneficial behavioral effects in PD rats was also examined. In normal CNS tissue, IGF-1 is secreted by neurons 34 , unlike other neurotrophic factors produced by glia, and acts upon nearby IGF-1 receptors in an autocrine manner. The use of neuronal-specific promoters, such as SYNp, to drive Igf-1 expression is therefore rational 31 . Indeed, SYNp has been extensively used to target expression of transgenes to neurons in vitro and in vivo 31, 43 . As shown, IPLVand IDLV-SYNp-eGFP vectors transduced predominantly neurons in both primary cell cultures and PD rat striata. Importantly, the in vivo data, consistent with other studies 43, 44 , demonstrated that striatal administration of vectors driven by SYNp led to eGFP detection in the SN, possibly due to anterograde axonal trafficking. At present, it is unclear whether the vectors or transgene-induced proteins are transported. However, an involvement of endocytosis likely explains the trans-synaptic transfer from neuron to neuron 45 . This appears as an advantage in PD therapy since a transgene can be administered into the striatum but provide therapeutic effects to both the striatum and the SN.
Technically, intrastriatal injection of vectors is simpler and safer than intranigral injection 46 although a possible higher dose (volume) of vectors is required for intrastriatal injection.
The most likely explanation for the failure of transgenic Igf-1 to mediate in vivo neuroprotection in our study is the insufficient levels of IGF-1 achieved. IGF-1 was previously used at 30-150 ng/ml in embryonic mesencephalic neuronal cultures 8, 47 , while we obtained ~5 ng/ml IGF-1 by transgenic expression in vitro, but still achieved complete neuroprotection. However, in vivo neuroprotection in 6-OHDA-lesioned rats has been shown with continuous intracerebroventricular IGF-1 infusion for a week at 100 µg/ml (10 µg in total) 21 , which is many orders of magnitude higher than the 15-35 pg/mg IGF-1 obtained in the current study. Ebert et al. 48 have previously reported the protective effects of IGF-1 on 6-OHDA-lesioned rats, which were achieved following striatal transplantation of neural progenitor cells expressing LV-IGF-1. The authors did not show at which levels IGF-1 provided such protection, and it could not be ruled out that other factors provided by the progenitor cells were involved. Indeed, in some systems progenitor cells can improve both cell survival and animal behavior in PD models against both 6-OHDA and MPTP toxicity 49, 50 . It is also noteworthy that to obtain similar protection on dopaminergic cell survival, previous investigators have used purified IGF-1 at concentrations about 30 times higher than that of GDNF 8, 51 . This is probably necessary due to the half-life of IGF-1 being less than 10 min whereas GDNF can last for 6-8 days 52, 53 . Since the doses Hioki, H, Kameda, H, Nakamura, H, Okunomiya, T, Ohira, K, Nakamura, K, et al. Astrocytes were identified by GFAP + staining, whereas (g) neurons were identified through Tuj1 + staining. Nuclei were stained blue with DAPI; GFAP + or Tuj1 + cells were stained red; scale bars are 50 µm. Data were analyzed by one-or two-way ANOVA followed by Bonferroni's post-hoc test.
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